FinnCap restated their under review rating on shares of Ekf Diagnostics Holding PLC (LON:EKF) in a research report report published on Tuesday morning.

Several other research firms have also recently weighed in on EKF. N+1 Singer restated a corporate rating on shares of Ekf Diagnostics Holding PLC in a report on Friday, October 7th. Panmure Gordon restated a buy rating and set a GBX 19 ($0.24) price target on shares of Ekf Diagnostics Holding PLC in a report on Monday, November 7th.

Shares of Ekf Diagnostics Holding PLC (LON:EKF) opened at 17.111 on Tuesday. The firm’s 50-day moving average is GBX 16.99 and its 200 day moving average is GBX 14.65. Ekf Diagnostics Holding PLC has a one year low of GBX 7.75 and a one year high of GBX 18.24. The firm’s market capitalization is GBX 73.37 million.

ILLEGAL ACTIVITY WARNING: This piece of content was first published by Financial Market News and is the sole property of of Financial Market News. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of U.S. and international copyright and trademark laws. The legal version of this piece of content can be read at

Ekf Diagnostics Holding PLC Company Profile

EKF Diagnostics Holdings plc is engaged in developing, manufacturing and supplying of products and services into the in-vitro diagnostic (IVD) market place. The Company manufactures and sells diagnostic instruments, reagents and certain ancillary products. The Company’s point-of-care range includes hemoglobin analyzers, HbA1c analyzers and glucose analyzers for use in the screening, monitoring and diagnosis of patients, as well as rapid tests for pregnancy and common infectious diseases.

Receive News & Ratings for Ekf Diagnostics Holding PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekf Diagnostics Holding PLC and related companies with's FREE daily email newsletter.